Friday, Nov. 27, 2015, 29 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,829.00 to $3,946,465.80.

Highlighted Stocks Traded by Insiders:

Tiptree Financial (TIPT) - FREE Research Report

Barnes Michael Gene, who is Executive Chairman at Tiptree Financial, bought 5,000 shares at $6.94 on Nov. 27, 2015. Following this transaction, the Executive Chairman owned 3.2 million shares meaning that the stake was boosted by 0.15% with the 5,000-share transaction.

The shares most recently traded at $7.00, up $0.06, or 0.83% since the insider transaction. Historical insider transactions for Tiptree Financial go as follows:

  • 4-Week # shares bought: 32,790
  • 12-Week # shares bought: 128,890
  • 24-Week # shares bought: 272,436

The average volume for Tiptree Financial has been 41,100 shares per day over the past 30 days. Tiptree Financial has a market cap of $244.1 million and is part of the financial sector and insurance industry. Shares are down 13.7% year-to-date as of the close of trading on Friday.

TipTree Financial Inc., formerly Care Investment Trust, operates as a real estate investment trust (REIT). It engages in originating and acquiring healthcare-related real estate and commercial mortgage debt. The stock currently has a dividend yield of 1.43%.

Exclusive Offer: Get the latest Stock Analysis on TIPT - FREE

TheStreet Quant Ratings

rates Tiptree Financial as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full

Tiptree Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Suburban Propane Partners (SPH) - FREE Research Report

Swift Jane, who is Director at Suburban Propane Partners, sold 1,500 shares at $29.81 on Nov. 27, 2015. Following this transaction, the Director owned 15,073 shares meaning that the stake was reduced by 9.05% with the 1,500-share transaction.

The shares most recently traded at $29.79, down $0.02, or 0.07% since the insider transaction. Historical insider transactions for Suburban Propane Partners go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 618
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 618
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 9,599

The average volume for Suburban Propane Partners has been 219,400 shares per day over the past 30 days. Suburban Propane Partners has a market cap of $1.8 billion and is part of the utilities sector and utilities industry. Shares are down 31.04% year-to-date as of the close of trading on Friday.

Suburban Propane Partners, L.P., through its subsidiaries, engages in the retail marketing and distribution of propane, fuel oil, and refined fuels. The stock currently has a dividend yield of 11.87%. The company has a P/E ratio of 21.7. Currently, there are 3 analysts who rate Suburban Propane Partners a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPH - FREE

TheStreet Quant Ratings

rates Suburban Propane Partners as a

hold

. The company's strongest point has been its expanding profit margins. At the same time, however, we also find weaknesses including a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share. Get the full

Suburban Propane Partners Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioDelivery Sciences International (BDSI) - FREE Research Report

Odonnell Francis E Jr, who is Director at BioDelivery Sciences International, sold 70,000 shares at $6.01 on Nov. 27, 2015. Following this transaction, the Director owned 2.0 million shares meaning that the stake was reduced by 3.37% with the 70,000-share transaction.

The shares most recently traded at $6.15, up $0.14, or 2.32% since the insider transaction. Historical insider transactions for BioDelivery Sciences International go as follows:

  • 4-Week # shares bought: 4,528
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 4,528
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 6,178
  • 24-Week # shares sold: 37,492

The average volume for BioDelivery Sciences International has been 1.8 million shares per day over the past 30 days. BioDelivery Sciences International has a market cap of $311.3 million and is part of the health care sector and drugs industry. Shares are down 50.83% year-to-date as of the close of trading on Friday.

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. Currently, there are 3 analysts who rate BioDelivery Sciences International a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BDSI - FREE

TheStreet Quant Ratings

rates BioDelivery Sciences International as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Get the full

BioDelivery Sciences International Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.